Industry Verticals »

All Categories

Insights »

About TMR »

Scleroderma Diagnostics and Therapeutics Market

Scleroderma Diagnostics and Therapeutics Market (Indication: Systemic and Localized; and Diagnostic Test Type: Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Scleroderma Diagnostics and Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 2.2 Bn in 2022
  • It is expected to grow at a CAGR of 8.7% from 2023 to 2031 and reach US$ 4.6 Bn by the end of 2031

Analyst Viewpoint

Growth in incidence of scleroderma and R&D of new therapeutics are expected to propel the scleroderma diagnostics and therapeutics market size during the forecast period. Various healthcare organizations are boosting awareness regarding the need for early diagnosis and treatment of scleroderma.

Preventive scleroderma management is gaining traction among healthcare professionals. Vendors in the market are conducting various studies for the treatment of Raynaud’s disease in scleroderma patients. They are seeking approval and launch of targeted therapies for scleroderma-associated complications to expand their product portfolio and increase their scleroderma diagnostics and therapeutics market share.

Scleroderma Diagnostics And Therapeutics Market

Market Introduction

Scleroderma is an autoimmune disease characterized by chronic hardening and tightening of the skin and connective tissues There are two main types of scleroderma: localized scleroderma and systemic sclerosis (systemic scleroderma). This classification is based on the severity of skin thickening, which adversely affects kidneys, lungs, gastrointestinal systems, and the heart.

Systemic sclerosis diagnostics can be challenging because its symptoms are diverse and can mimic other conditions. Vendors in the global scleroderma diagnostics and therapeutics industry are investing in R&D activities in scleroderma and autoimmune diseases and several first-in-class curatives are under clinical development. Approval and launch of novel therapeutics is expected to spur the scleroderma diagnostics and therapeutics market growth in the near future.

R&D of New Therapeutics

Scleroderma is a complex autoimmune disease. Various studies are focusing on identifying the specific proteins or molecular pathways involved in the pathogenesis of the disease. ‘LMCD1’ protein could be a potential therapeutic target for patients suffering from systemic sclerosis. Those infected with interstitial lung disease (ILD) have a higher presence of LMCD1 protein as compared to healthy people. Thus, various studies are focused on LMCD1 as a potential therapeutic target for patients suffering from scleroderma. Rise in investment in such studies is projected to augment the scleroderma diagnostics and therapeutics market value in the next few years.

Some studies have reported that an exclusive macrophage – an immune cell capable of removing dead cells or bacteria, plays an important role in scarring in lungs and skin along with chronic inflammation. These studies are looking forward to targeting this macrophage for the development of effective scleroderma therapeutics.

A study published in the Journal of Scleroderma and Related Disorders (JSRD) in February 2022 reported that immunosuppressive drugs (methotrexate, in particular) help reduce scleroderma symptoms to a greater extent. In October 2022, clinicians from the Michigan Medicine and the University of Pittsburgh received approval from the U.S. FDA for tofacitinib for the treatment of scleroderma. Thus, approval and launch of new therapeutics is fueling the scleroderma diagnostics and therapeutics market progress during the forecast period.

Growth in Incidence of Scleroderma

Scleroderma is common in women aged between 30 and 50 who undergo pregnancy, lactating, and menopause. Raynaud’s phenomenon is one of the earliest manifestations of this ailment. It is characterized by decreased blood flow to the fingers (vasospasms) and is induced by stress or cold temperature. Finger ulcers, joint and muscle pain, dilated blood vessels, and skin tightening could develop if the condition is not treated on time. According to the National Organization for Rare Disorders, systemic scleroderma affects 38 to 341 individuals per million throughout the world and develops in 8 to 56 individuals per million each year.

Rise in Demand for Preventive Healthcare Driving Scleroderma Diagnostics and Therapeutics Market Expansion

Systemic sclerosis is linked with noticeable morbidity inclusive of disability, pain, depression, and reduced quality of life. The subsequent effects include a reduction in physical activity or physical capacity to perform daily chores. This ailment may result in the weakening of muscles along with impairment in oxygen consumption and transport. Therefore, healthcare personnel are recommending preventive healthcare. It implies mechanisms such as modulation of redox homeostasis and/or stress-response proteins that enhance functional and muscular performance and endocrine-metabolic, mental, and cardiovascular health.

Regional Outlook

According to the latest scleroderma diagnostics and therapeutics market forecast, North America is expected to hold largest share from 2023 to 2031. Presence of a well-established healthcare sector and rise in R&D of new therapeutics are fueling market dynamics of the region. Several non-profit organizations are raising awareness regarding scleroderma. The National Scleroderma Foundation focuses on medical research, promotes awareness about scleroderma, and renders support and education to those suffering from the disease.

Surge in incidence of scleroderma is propelling the scleroderma diagnostics and therapeutics market statistics in Europe and Asia Pacific. According to the National Center for Biotechnology Information, the reported prevalence of systemic sclerosis in Europe was 13.5-44.3 per 100,000 individuals. suffer from. The reported prevalence of scleroderma was 24.4 per 100,000 individuals in Thailand.

Analysis of Key Players

Most scleroderma diagnostics and therapeutics vendors are conducting phased trials regarding scleroderma treatment. Innovative approaches in scleroderma clinical trials include targeted therapies, stem cell therapy, and precision medicine. Johnson & Johnson Services, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceuticals Holdings Inc., Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Sanofi S.A., Pfizer Inc., F. Hoffmann-La Roche AG, and Merck & Co., Inc. are key players operating in this market.

Each of these players has been profiled in the scleroderma diagnostics and therapeutics market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In July 2022, Aisa Pharma Inc. reported that positive results were witnessed regarding its phase-2 study of Profervia – an oral calcium-channel antagonist indicated for the treatment of Raynaud’s disease in scleroderma patients.
  • In April 2022, aTyr Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) granted the company orphan drug designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis
  • In January 2022, Paracrine, Inc. announced that the U.S. FDA granted full approval of its Investigational Device Exemption (IDE) to conduct a pivotal trial titled Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells: A Randomized, Double-blind, Placebo-Controlled Study - the “STAR II Trial.”

Scleroderma Diagnostics and Therapeutics Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 2.2 Bn
Market Forecast Value in 2031 US$ 4.6 Bn
Growth Rate (CAGR) 8.7%
Forecast Period 2023-2031
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia & CIS
  • China
  • India
  • ASEAN
  • GCC
  • South Africa
  • Brazil
  • Mexico
Market Segmentation
  • Indication
    • Systemic
    • Localized
  • Drug Class
    • Corticosteroids
    • Immunosuppressive Agents
    • Endothelin Receptor Agonists
    • Calcium Channel Blockers
    • PDE-5 Inhibitors
    • Chelating Agents
    • Prostacyclin Analogues
    • H2 Blockers
    • Proton Pump Inhibitors
    • ACE Inhibitors
  • Diagnostic Test Type
    • Skin Biopsy
    • Imaging Techniques
    • Blood Test
    • Electrocardiogram and Echocardiogram
    • Pulmonary Function Tests
Companies Profiled
  • Johnson & Johnson Services, Inc.
  • Boehringer Ingelheim
  • Bayer AG
  • Cytori Therapeutics, Inc.
  • Corbus Pharmaceuticals Holdings Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
Scope for Customization Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the scleroderma diagnostics and therapeutics market in 2022?

It was valued at US$ 2.2 Bn in 2022

How is the scleroderma diagnostics and therapeutics business expected to grow during the forecast period?

It is projected to grow at a CAGR of 8.7% from 2023 to 2031

What are the key factors driving the demand for scleroderma diagnostics and therapeutics?

Growth in incidence of scleroderma and R&D of new therapeutics

Which region is expected to dominate the scleroderma diagnostics and therapeutics sector?

North America is estimated to dominate during the forecast period

Who are the key scleroderma diagnostics and therapeutics manufacturers?

Johnson & Johnson Services, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceuticals Holdings Inc., Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Sanofi S.A., Pfizer Inc., F. Hoffmann-La Roche AG, and Merck & Co., Inc.

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Key Facts and Figures

    1.4. Trends Impacting Market

    1.5. TMR’s Growth Opportunity Wheel

2. Market Overview

    2.1. Market Segmentation

    2.2. Market Trends

    2.3. Market Dynamics

        2.3.1. Drivers

        2.3.2. Restraints

        2.3.3. Opportunities

    2.4. Porter’s Five Forces Analysis

    2.5. Regulatory Analysis

    2.6. Value Chain Analysis

        2.6.1. List of Raw Material Suppliers

        2.6.2. List of Key Manufacturers

        2.6.3. List of Suppliers/ Distributors

        2.6.4. List of Potential Customers

    2.7. Product Specification Analysis

    2.8. Overview of Manufacturing Process

    2.9. Cost Structure Analysis

3. COVID-19 Impact Analysis

4. Price Trend Analysis

5. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Drug Class, 2023–2031

    5.1. Introduction and Definitions

    5.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        5.2.1. Corticosteroids

        5.2.2. Immunosuppressive Agents

        5.2.3. Endothelin Receptor Agonists

        5.2.4. Calcium Channel Blockers

        5.2.5. PD5-Inhibitors

        5.2.6. Chelating Agents

        5.2.7. Prostacyclin Analogues

        5.2.8. H2 Blockers

        5.2.9. Proton Pump Inhibitors

        5.2.10. ACE Inhibitors

    5.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Drug Class

6. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Indication, 2023–2031

    6.1. Introduction and Definitions

    6.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        6.2.1. Systemic

        6.2.2. Localized

    6.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Indication

7. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnostic Test Type, 2023–2031

    7.1. Introduction and Definitions

    7.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        7.2.1. Skin Biopsy

        7.2.2. Imaging Techniques

        7.2.3. Blood Test

        7.2.4. Electrocardiogram and Echocardiogram

        7.2.5. Pulmonary Function Tests

    7.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Diagnostic Test Type

8. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Region, 2023–2031

    8.1. Key Findings

    8.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Region, 2023–2031

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Middle East & Africa

        8.2.5. Latin America

    8.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Region

9. North America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023–2031

    9.1. Key Findings

    9.2. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

    9.3. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

    9.4. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    9.5. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country, 2023–2031

        9.5.1. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        9.5.2. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        9.5.3. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        9.5.4. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        9.5.5. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        9.5.6. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    9.6. North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

10. Europe Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023–2031

    10.1. Key Findings

    10.2. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

    10.3. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

    10.4. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    10.5. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031

        10.5.1. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        10.5.2. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        10.5.3. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        10.5.4. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        10.5.5. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        10.5.6. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        10.5.7. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        10.5.8. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        10.5.9. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        10.5.10. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        10.5.11. Italy. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        10.5.12. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        10.5.13. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        10.5.14. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        10.5.15. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        10.5.16. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        10.5.17. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        10.5.18. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    10.6. Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

11. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023–2031

    11.1. Key Findings

    11.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class

    11.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

    11.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    11.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031

        11.5.1. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        11.5.2. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        11.5.3. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        11.5.4. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        11.5.5. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        11.5.6. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        11.5.7. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        11.5.8. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        11.5.9. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        11.5.10. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        11.5.11. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        11.5.12. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        11.5.13. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        11.5.14. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        11.5.15. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    11.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

12. Latin America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023–2031

    12.1. Key Findings

    12.2. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

    12.3. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

    12.4. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    12.5. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031

        12.5.1. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        12.5.2. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        12.5.3. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        12.5.4. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        12.5.5. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        12.5.6. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        12.5.7. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        12.5.8. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        12.5.9. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    12.6. Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

13. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023–2031

    13.1. Key Findings

    13.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

    13.3. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

    13.4. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    13.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031

        13.5.1. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        13.5.2. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        13.5.3. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        13.5.4. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        13.5.5. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        13.5.6. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

        13.5.7. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023–2031

        13.5.8. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023–2031

        13.5.9. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

    13.6. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

14. Competition Landscape

    14.1. Global Scleroderma Diagnostics and Therapeutics Company Market Share Analysis, 2022

    14.2. Company Profiles (Details – Overview, Financials, Recent Developments, and Strategy)

        14.2.1. Johnson & Johnson Services, Inc.

            14.2.1.1. Company Description

            14.2.1.2. Business Overview

            14.2.1.3. Financial Overview

            14.2.1.4. Strategic Overview

        14.2.2. Boehringer Ingelheim

            14.2.2.1. Company Description

            14.2.2.2. Business Overview

            14.2.2.3. Financial Overview

            14.2.2.4. Strategic Overview

        14.2.3. Bayer AG

            14.2.3.1. Company Description

            14.2.3.2. Business Overview

            14.2.3.3. Financial Overview

            14.2.3.4. Strategic Overview

        14.2.4. Cytori Therapeutics, Inc.

            14.2.4.1. Company Description

            14.2.4.2. Business Overview

            14.2.4.3. Financial Overview

            14.2.4.4. Strategic Overview

        14.2.5. Corbus Pharmaceuticals Holdings Inc.

            14.2.5.1. Company Description

            14.2.5.2. Business Overview

            14.2.5.3. Financial Overview

            14.2.5.4. Strategic Overview

        14.2.6. Cumberland Pharmaceuticals, Inc.

            14.2.6.1. Company Description

            14.2.6.2. Business Overview

            14.2.6.3. Financial Overview

            14.2.6.4. Strategic Overview

        14.2.7. Gilead Sciences, Inc.

            14.2.7.1. Company Description

            14.2.7.2. Business Overview

            14.2.7.3. Financial Overview

            14.2.7.4. Strategic Overview

        14.2.8. Sanofi S.A.

            14.2.8.1. Company Description

            14.2.8.2. Business Overview

            14.2.8.3. Financial Overview

            14.2.8.4. Strategic Overview

        14.2.9. Pfizer Inc.

            14.2.9.1. Company Description

            14.2.9.2. Business Overview

            14.2.9.3. Financial Overview

            14.2.9.4. Strategic Overview

        14.2.10. F. Hoffmann-La Roche AG

            14.2.10.1. Company Description

            14.2.10.2. Business Overview

            14.2.10.3. Financial Overview

            14.2.10.4. Strategic Overview

        14.2.11. Merck & Co., Inc.

            14.2.11.1. Company Description

            14.2.11.2. Business Overview

            14.2.11.3. Financial Overview

            14.2.11.4. Strategic Overview

15. Primary Research: Key Insights

16. Appendix

List of Tables

Table 01: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023–2031

Table 02: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023–2031

Table 03: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

Table 04: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Region, 2023–2031

Table 05: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country, 2023–2031

Table 06: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023–2031

Table 07: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023–2031

Table 08: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

Table 09: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 10: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023–2031

Table 11: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023–2031

Table 12: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

Table 13: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 14: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023–2031

Table 15: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023–2031

Table 16: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

Table 17: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 18: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023–2031

Table 19: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023–2031

Table 20: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

Table 21: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 22: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023–2031

Table 23: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023–2031

Table 24: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023–2031

List of Figures

Figure 01: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2031

Figure 02: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Drug Class, 2022

Figure 03: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Drug Class, 2022

Figure 04: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Indication, 2022

Figure 05: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Indication, 2022

Figure 06: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Diagnostic Test Type, 2022

Figure 07: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Diagnostic Test Type, 2022

Figure 08: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Region, 2022

Figure 09: Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, 2023–2031

Figure 10: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031

Figure 11: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031

Figure 12: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031

Figure 13: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031

Figure 14: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031

Figure 15: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031

Figure 16: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Region, 2023 and 2031

Figure 17: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 19: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country, 2023 and 2031

Figure 21: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031

Figure 22: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031

Figure 23: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031

Figure 24: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 25: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

Figure 26:North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022–2031

Figure 27: Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 28: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 30: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031

Figure 31: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031

Figure 32: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031

Figure 33: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 34: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

Figure 35: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022–2031

Figure 36: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 37: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 39: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031

Figure 40: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031

Figure 41: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031

Figure 42: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 43: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

Figure 44: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022–2031

Figure 45: Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 46: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 48: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031

Figure 49: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031

Figure 50: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031

Figure 51: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 52: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

Figure 53: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022–2031

Figure 54: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 55: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 57: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031

Figure 58: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031

Figure 59: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031

Figure 60: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 61: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

Figure 62: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved

Scleroderma Diagnostics and Therapeutics Market

Schedule a Call